LQDA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

83.46M

+2761.17%

-0.204

-54.72%

92.21M

+2855.34%

0.080

-117.78%

119.16M

+1248.43%

0.330

-167.35%

Estimates Revision

The market is revising Upward the revenue expectations for Liquidia Corporation (LQDA) for FY2025, with the revenue forecasts being adjusted by 116.35% over the past three months. During the same period, the stock price has changed by 31.35%.

Revenue Estimates for FY2025

Revise Upward

+116.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-53.08%

In Past 3 Month

Stock Price

Go Up

+31.35%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 34.190

Low

31.00

Averages

47.50

High

67.00

Current: 34.190

Low

31.00

Averages

47.50

High

67.00

H.C. Wainwright

Buy

maintain

$35 -> $50

2025-11-04

Reason

H.C. Wainwright

Price Target

$35 -> $50

2025-11-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Liquidia to $50 from $35 and keeps a Buy rating on the shares. The firm says the company's profitability "arrived early" with Liquidia reporting "impressive" Q3 earnings. The investment story "has shifted from a binary launch to a profit driven story," the analyst tells investors in a research note.

Raymond James

Strong Buy

maintain

$41 -> $47

2025-11-04

Reason

Raymond James

Price Target

$41 -> $47

2025-11-04

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Liquidia to $47 from $41 and keeps a Strong Buy rating on the shares. Liquidia's Q3 earnings were driven by strong Yutrepia performance in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with net sales of $51.7M, over triple consensus estimates, and profitability achieved ahead of schedule, the analyst tells investors in a research note. Yutrepia accounted for roughly 75% of revenue growth in its market, aided by major PBM contracts and easing new-patient restrictions. Unadjusted peak sales estimates have been raised to about $2B from $1.1B, reflecting exceptional early launch momentum.

BofA

Buy

maintain

$37 -> $39

2025-11-03

Reason

BofA

Price Target

$37 -> $39

2025-11-03

maintain

Buy

Reason

BofA raised the firm's price target on Liquidia to $39 from $37 and keeps a Buy rating on the shares after the company reported Q3 net sales that beat BofA and the Street's sales forecasts. The firm believes shares are flat given the overhang on pending patent litigation that risks narrowing Yutrepia's indication statement, but it thinks today's results confirm Yutrepia's value proposition in the pulmonary hypertension market, a faster ramp to peak sales and much greater revenue opportunity from the PAH indication, the analyst tells investors.

Jefferies

Buy

maintain

$43 -> $45

2025-11-03

Reason

Jefferies

Price Target

$43 -> $45

2025-11-03

maintain

Buy

Reason

Jefferies raised the firm's price target on Liquidia to $45 from $43 and keeps a Buy rating on the shares following a strong Q3 that beat consensus and the firm's "bullish" expectations. Liquidia also hit operating profitability in Q3, two quarter's ahead of management's expectations and one quarter ahead of the firm's "already bullish estimates," the analyst added.

Jefferies

NULL

Buy

initiated

$31 -> $43

2025-08-15

Reason

Jefferies

Price Target

$31 -> $43

2025-08-15

initiated

NULL

Buy

Reason

Jefferies assumed coverage of Liquidia (LQDA) with a Buy rating and a price target of $43, up from $31. The firm expects Yutrepia to beat FY25 estimates and for the company to hit profitability in Q4 of 2025, adding that it views it as "highly unlikely" Yutrepia is pulled off the market due to United Therapeutics' (UTHR) patent litigation.

BofA

Buy

upgrade

$23 -> $35

2025-08-12

Reason

BofA

Price Target

$23 -> $35

2025-08-12

upgrade

Buy

Reason

BofA raised the firm's price target on Liquidia to $35 from $23 and keeps a Buy rating on the shares. The company reported solid 2Q results with an inventory stocking-driven sales beat, but more importantly, the management disclosed strong lead indicators for the Yutrepia launch that included over 550 new Yutrepia patient starts and over 900 unique prescription referrals, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Liquidia Corp (LQDA.O) is 17.45, compared to its 5-year average forward P/E of -10.82. For a more detailed relative valuation and DCF analysis to assess Liquidia Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.82

Current PE

17.45

Overvalued PE

9.21

Undervalued PE

-30.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.71

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

6.06

Undervalued EV/EBITDA

-17.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23.45

Current PS

0.00

Overvalued PS

38.09

Undervalued PS

8.82

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LQDA News & Events

Events Timeline

No data

News

3.0

06:08 AMYahoo Finance

Is It Still Worth Considering Liquidia After Its 1,051% Increase Over Five Years?

4.5

11-19Barron's

Healthcare Sector Gains Traction: 3 Stocks Show Positive Trends.

9.0

11-19NASDAQ.COM

From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?

People Also Watch

Frequently Asked Questions

What is Liquidia Corp (LQDA) stock price today?

The current price of LQDA is 34.19 USD — it has increased 2.43 % in the last trading day.

What is Liquidia Corp (LQDA)'s business?

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

What is the price predicton of LQDA Stock?

What is Liquidia Corp (LQDA)'s revenue for the last quarter?

Liquidia Corp revenue for the last quarter amounts to 54.34M USD, increased 1121.72 % YoY.

What is Liquidia Corp (LQDA)'s earnings per share (EPS) for the last quarter?

Liquidia Corp. EPS for the last quarter amounts to -0.04 USD, decreased -86.67 % YoY.

What changes have occurred in the market's expectations for Liquidia Corp (LQDA)'s fundamentals?

How many employees does Liquidia Corp (LQDA). have?

Liquidia Corp (LQDA) has 157 emplpoyees as of December 16 2025.

What is Liquidia Corp (LQDA) market cap?

Today LQDA has the market capitalization of 2.97B USD.